protein engineering


Also found in: Encyclopedia, Wikipedia.

protein engineering

the deliberate design and production of PROTEINS with desired properties by direct chemical synthesis and modification, or by GENETIC ENGINEERING from SYNTHETIC GENES or modified DNA sequences. For example, PROTEASES have been engineered to be more effective when used in biological washing powders.
References in periodicals archive ?
PUCHHEIM, Germany -- Sloning BioTechnology GmbH, the worldwide leading supplier of combinatorial gene libraries, received additional investments from all of its institutional shareholders: HBM BioVentures, LBBW Venture, DEWB and KfW to finance the company's ongoing commercial growth strategy in the field of protein engineering.
According to the company, the new software, enabling faster plate read times of one hour, lower reagent consumption, FDA 21 CFR Part 11 tools and LIMS connectivity, was introduced at the recently concluded Protein Engineering Summit conference in Boston.
Our unique protein engineering capabilities allow us to rapidly build libraries around almost any bispecific construct.
Central themes: bioinformatics, protein engineering, regenerative medicine and financing
M2 EQUITYBITES-July 15, 2014-Codexis licenses its protein engineering platform technology to GlaxoSmithKline
Bio-IT World Europe and PEGS Europe: The Protein Engineering Summit, make debut in Hannover, Germany
M2 PHARMA-July 15, 2014-Codexis licenses its protein engineering platform technology to GlaxoSmithKline
M2 EQUITYBITES-June 19, 2014-Agilent Technologies unveils cost-effective protein engineering system QuikChange HT
com) to optimize an undisclosed antibody using Zymeworks' ZymeCAD[TM] suite of predictive protein engineering tools and XOMA's innovative Targeted Affinity Enhancement[TM] (TAE[TM]) technology for antibody mutagenesis and optimization.
As part of this collaboration, Synthetic Biologics Inc plans to utilise Intrexon's comprehensive suite of proprietary technologies, including their extensive Protein Engineering assets, mAbLogix, and LEAP platforms, to develop biologics to specifically and rapidly neutralise/clear pathogens that cause serious infectious diseases and other diseases.
ALLOZYNE's proprietary biocipher technology uses the potential of biological protein engineering and medicinal chemistry to create novel and enhanced protein therapeutics.